We are international
Donate
• about myeloma TEXT SIZE   
   back

Spring 2004 Volume 5, Issue 10:
Atiprimod: A New Drug Candidate in Early-Stage Development for Myeloma
By Gary S. Jacob, PhD
CEO, CSO
Callisto Pharmaceuticals
Atiprimod has a very interesting history, providing yet another example of a drug candidate that begins its story as a potential treatment for a wholly different disease indication.
04.26.04

Be the first to comment

 related articles